GINGERA MIDLIFE, UNDERSTOOD
← The reading room
Hormones & treatment · 6 MIN READ

ACP and ACOG Align: Hormone Therapy Returns to First Line for Hot Flashes and Night Sweats

Full original restored

Goals, certainty, risk and access explain why “first line” does not mean the same prescription for everyone.

Editorial image
In this article
Complete manuscript restored from the archive, with a full English translation. Original medical claims have been preserved for review; medical and regional terminology review remain pending. This is educational reading, not individual medical advice.

ACP and ACOG Align: Hormone Therapy Returns to First Line for Hot Flashes and Night Sweats

Two leading US societies speak in the same month—explaining the ranking of nonhormonal options and why phytoestrogens are excluded

Written 2026-10-27 · Intended readers: obstetrician-gynecologists / endocrinologists / internists / family physicians and patients interested in evidence

In an internal-medicine clinic, 52-year-old Ms. Zhou reports that hot flashes and night sweats are disrupting her sleep. Her doctor opens two recently updated guidelines: ACOG's (American College of Obstetricians and Gynecologists) Clinical Practice Guideline No.13 from 10-15, and the ACP (American College of Physicians) guideline published in Annals of Internal Medicine on 10-6. After reading them, the conclusion is:

This time, the two are largely saying the same thing

.

This is not a coincidence, but a concentrated expression of the 2026 menopause-treatment consensus “returning from fear to evidence.” Below, we unpack the ACP guideline's key points, its alignment with ACOG, and the underlying mechanisms and literature.

1

One. What exactly is this ACP guideline?

The ACP clinical guideline, Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: A Clinical Guideline From the American College of Physicians, was authored by Qaseem et al. and published online in Annals of Internal Medicine on 2026-10-6. Its accompanying systematic review and network meta-analysis (Diem et al., same journal) included 90 studies (102 publications). The methodology used the GRADE framework and, for the first time in its menopause medication recommendations, systematically incorporated economic evidence and patient values/preferences.

Original article illustration

Old Porvoo riverfront, Finland | Photograph by:

kallerna

,

CC BY-SA 3.0

Core scope

The focus is drug treatment of vasomotor symptoms (VMS: hot flashes + night sweats). VMS are the most widespread menopausal symptoms, affecting up to 80% of women. They may persist for years after menopause, substantially disrupting daily activities and sleep and reducing quality of life. The guideline specifically emphasizes that clinicians should ask proactively about VMS experiences, because many women will not raise the subject themselves.

2

Two. First line: a strong recommendation for MHT (high-certainty evidence)

ACP's highest-level recommendation (strong recommendation, high-certainty evidence) is:

  • With a uterus: combined estrogen and progestogen;
  • Without a uterus: estrogen alone.

This fully aligns with ACOG No.13's central position: MHT (called HT/HRT in US guidelines) returns to first line.

Rationale: why a strong recommendation is justified

  • WHI reanalysis changed understanding: Reanalysis revised the early Women's Health Initiative “risk narrative”—risk depends heavily on age, timing of initiation, hormone type, and baseline health. The benefit/risk ratio is favorable for those <60 or within 10 years of menopause without contraindications.
  • Regulatory easing: In 2025, the FDA removed boxed warnings about cardiovascular disease, breast cancer, and possible dementia from MHT labels, providing a basis for upgrading recommendations.
  • Established efficacy: Systematic reviews show that combined estrogen/progestogen and estrogen alone both significantly reduce VMS frequency and severity and improve menopause-related quality of life versus placebo; both are rated high-value treatments.
  • Timing window: Consistent with ACOG, for those with an indication who choose MHT, initiate before age 60 or within 10 years after menopause.

Original article illustration

Saksun village, Faroe Islands | Photograph by:

MiroRosa

,

CC BY-SA 4.0

3

Three. Nonhormonal options: ACP provides a clear “tiered” pathway

For people with contraindications to or intolerance of estrogen therapy, ACP uses GRADE “conditional recommendations” to set a clear hierarchy (its most notable formal difference from ACOG):

TierMedicineEvidence certainty
Second lineSNRI: desvenlafaxineor venlafaxineModerate certainty
Third lineSSRI: escitalopramor paroxetineLow certainty
gabapentinLow certainty
NK receptor antagonists: fezolinetantor elinzanetantModerate certainty

Rationale and an intriguing detail

NK receptor antagonists (blocking NKB signaling in hypothalamic KNDy neurons) have “moderate” evidence certainty and clear efficacy, yet ACP places them third line because of its distinctive economic perspective: evidence rates fezolinetant as a “low-value treatment,” while elinzanetant has a higher wholesale acquisition cost. In other words, ACP asks not only “does it work?” but “is it worth it for patients and the system?”

By contrast, ACOG takes a less stratified position: it recommends SSRIs/SNRIs and NK antagonists alongside each other and includes nonpharmacological approaches such as CBT, mindfulness, exercise, hypnosis, and acupuncture—a broader scope, but a less explicit hierarchy.

Original article illustration

Djurgården ferry waterfront, Stockholm, Sweden | Photograph by:

Arild Vågen

,

CC BY-SA 4.0

4

Four. Phytoestrogens / herbal products: not supported

A shared boundary from the two societies:

Phytoestrogens such as soy isoflavones and various herbal supplements

lack evidence of efficacy and safety, are not regulated by the FDA, and have not undergone purity and safety testing

and therefore are not recommended as reliable alternatives for VMS.

Rationale: why “phytoestrogens” do not hold up

  • Isoflavones, lignans, coumarins, and similar compounds in plant foods contain only phytoestrogens—SERM-like compounds that bind estrogen receptors weakly, at only 1/100~1/10000 the affinity of estradiol; they are not hormones and cannot replace MHT.
  • Trace true hormones in animal foods undergo digestion and hepatic first-pass metabolism, at quantities far below endogenous secretion, and cannot reach therapeutic concentrations.
  • Marketed supplements lack standardized doses and quality control, with no high-quality RCT support for efficacy or long-term safety; their “natural” label instead creates a false sense of safety.

This publication's earlier menopause-nutrition education also emphasized that the NAMS 2023 nonhormonal management position statement lists soy foods / soy extracts as “not recommended” (evidence level II). Writing about soy foods should use “modest and inconsistent evidence, currently not recommended as treatment,” rather than “recommended by the society.”

Original article illustration

Copenhagen Opera House, Denmark | Photograph by:

Kritzolina

,

CC BY-SA 4.0

5

Five. How ACP and ACOG align (and differ)

Dimension ACP (2026-10-06) ACOG No.13 (2026-10-15)
First-line VMS treatment Strong recommendation for MHT (high certainty) Strong recommendation for MHT (moderate certainty)
Position of nonhormonal treatment Explicit tiers: SNRIs second line; SSRIs/gabapentin/NK antagonists third line SSRIs/SNRIs and NK antagonists recommended alongside each other; includes nonpharmacological options
Phytoestrogens/herbs Not supported (insufficient evidence, no regulation) Not supported (insufficient evidence, no FDA regulation)
Initiation window <60 or within 10 years of menopause <60 or within 10 years of menopause
Shared decision-making Emphasized (including financial burden and access) Emphasized (including health equity)
Distinctive feature Systematically includes economic evidence; focuses on VMS Broader scope (sleep, mood; GSM expected in 2027); highlights health equity

Alignment in one sentence: the societies closely agree on “who should receive first-line treatment, who should use nonhormonal options, and what to avoid”; differences mainly involve nonhormonal “ranking” and breadth of guideline coverage.

6

Six. Key clinical implications

  • Ask proactively: Do not wait for patients to speak; ask about VMS starting in their 40s, and educate them about the natural course, including “how long symptoms may last,” to normalize the experience.
  • Lowest effective dose: ACP recommends the lowest effective dose; network meta-analysis suggests greater efficacy with high-dose estrogen but an uncertain overall benefit/risk balance, so do not increase doses indiscriminately.
  • Assess efficacy at 8–12 weeks, then reassess periodically; common practice avoids initiation at >60 or >10 years since menopause and often limits treatment to 3–5 years (although optimal duration is unknown and should be individualized).
  • Route selection: For high VTE/CVD risk (including BMI>30), prioritize transdermal treatment (see this publication's BMS/NICE 2026 article); with coexisting depression, SSRIs may be more suitable even if “third line”; with osteoporosis, estrogen's bone benefits may take priority in the assessment.
  • Explain limitations: Evidence comes mainly from healthy White postmenopausal women aged 49–57; only 8 studies involved perimenopause, and those with previous breast/endometrial cancer, CVD, stroke, or VTE were excluded. Most trials lasted only 12 weeks, limiting assessment of rare long-term harms.

Original article illustration

Kirkjufell in summer, Iceland | Photograph by:

Jakub Hałun

,

CC BY 4.0

Quick-reference reading for clinicians

  1. Qaseem A, et al. Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: ACP Clinical Guideline. Ann Intern Med. 6 Oct 2026.
  2. Diem S, et al. Pharmacologic treatments for female menopausal vasomotor symptoms: systematic review and meta-analysis for ACP. Ann Intern Med. 6 Oct 2026.
  3. Castaneda R, Faubion SS. The New ACP Clinical Guideline for Pharmacologic Treatment of Menopausal VMS. Ann Intern Med. 2026 (editorial).
  4. ACOG. Clinical Practice Guideline No.13: Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms. Obstet Gynecol. 2026;148:e345–e369.
  5. NAMS 2022 Hormone Therapy Position Statement. Menopause. 2022;29:767–794.
  6. NAMS 2023 Nonhormone Therapy Position Statement. Menopause. 2023;30:573–590.
  7. Lederman S, et al. SKYLIGHT 1 (fezolinetant). Lancet. 2023.
  8. Rance NE, et al. KNDy neurons and hot flushes hypothesis. Front Neuroendocrinol. 2013.
  9. FDA. Removal of boxed warnings on MHT labeling. 2025.
  10. ACP Newsroom. ACP recommends hormonal therapy as first-line for menopausal VMS. 5 Oct 2026.

Boundary statement:

This article is an evidence-based review and academic compilation drawing on public guidelines and literature,

not diagnosis, treatment advice, or a recommendation for any product

. Clinical decisions must reflect individual circumstances, follow current guidance in the relevant country, and be made jointly by a fully informed patient and treating clinician. MHT initiation, formulation, dose, and duration require individualized implementation after assessment of contraindications.

Original article illustration

Tromsø harbor, Norway | Photograph by:

Godot13

,

CC BY-SA 4.0

· Health education for women 40+

This publication follows evidence-based, noncommercial principles. Its focus remains:

Informed choice + bringing records to consultations + shared decisions with clinicians

.

If you have questions about this article, bring your own medical history and test results to discuss with your treating clinician.

SOURCE NOTES

Read the source material

The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.

GINGERA / COMMUNITY

A good question starts a conversation.

Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.

Create a free accountDiscuss hot flashes